Ratings Takeda Pharmaceutical Company Limited Sao Paulo

Equities

TAKP34

BRTAKPBDR006

Market Closed - Sao Paulo Other stock markets 09:51:04 2024-06-12 EDT			5-day change	1st Jan Change
72.31 ^BRL	+0.88%		+1.85%	+4.55%

06-14	Takeda Signs Option Agreement with Ascentage to License Leukemia Drug	MT
06-14	Takeda Pharmaceutical Company Limited Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, Third-Generation BCR-ABL Tyrosine Kinase Inhibitor	CI

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The company's share price in relation to its net book value makes it look relatively cheap.
This company will be of major interest to investors in search of a high dividend stock.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
The opinion of analysts covering the stock has improved over the past four months.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

According to forecast, a sluggish sales growth is expected for the next fiscal years.
The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
One of the major weak points of the company is its financial situation.
With an expected P/E ratio at 46.58 and 64.08 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
TAKEDA PHARMACEUTICAL COMPANY LIMITED	+4.55%	41.3B	-
ELI LILLY AND COMPANY	+50.70%	791B	C+
NOVO NORDISK A/S	+41.96%	630B	B
JOHNSON & JOHNSON	-7.15%	350B	C+
MERCK & CO., INC.	+18.77%	328B	B-
ABBVIE INC.	+8.79%	298B	C+
ASTRAZENECA PLC	+18.02%	246B	B+
ROCHE HOLDING AG	+1.27%	225B	A+
NOVARTIS AG	+11.95%	218B	B-
AMGEN INC.	+3.68%	160B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes